Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: ICICI Securities Limited

Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Expensive Performer

2793.6000 24.50 (0.88%)

NSE May 02, 2025 15:31 PM

26.91% Gain from 52W Low

Volume: 137.7K

Dr. Lal Pathlabs Ltd.

26 Apr 2025

2793.60

0.88%

Decent quarter, limited headroom for margins expansion

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q4FY25 results were slightly better than our expectation. Outperformance was driven by higher sample volumes (up 9.5% YoY) and realisation improvement.

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2746.5